Rituximab in Patients With ST-elevation Myocardial Infarction

Summary

The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left ventricular systolic function, using CMR, in patients who have had an acute anterior STEMI. Following the sponsor's decision to stop enrolment in the 200 mg arm, the primary objective of the study is to evaluate the efficacy of a single 1000 mg dose of rituximab versus placebo. The primary endpoint is the left ventricular ejection fraction (LVEF) by CMR at 6 months.

Timeline

Start

2022-06-01

Primary completion

2027-11

Completion

2028-05

Publications

• Yerly A, van der Vorst EPC, Schindewolf M, Kotelis D, Noels H, Doring Y. Chemokine-receptor-guided B-cell immunity in cardiovascular disease. Basic Res Cardiol. 2025 Dec;120(6):1075-1090. doi: 10.1007/s00395-025-01140-x. Epub 2025 Sep 23.

Drugs

Indications